As seen with President Trump measuring Oxygen Saturation, SpO2 is key in screening and managing COVID-19 symptoms
Los Angeles, CA, Nov. 19, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce the integration of SpO2 into its Vital Intelligence assessment technology.
The technology gauges blood oxygen saturation from a video stream of a person’s face.
Also known as SpO2, blood oxygen saturation is a measure of how well the lungs absorb oxygen and the circulatory system transports oxygenated blood. An individual’s SpO2 level is usually measured using connected sensors that project light through a finger or earlobe and, until now, there has been no real means to make a non-contact assessment. In the COVID-19 era, a low SpO2 level has risen to prominence as an important symptom of individuals with COVID-19.
SpO2 appraisal as part of Draganfly’s Vital Intelligence Assessment Technology, which also measures key indicators like heart rate and respiratory rate is designed to increase the likelihood of detecting illness using a camera instead of contact sensors. This type of contactless screening reduces the risk of cross-infection, can be much faster and can be used remotely as a powerful telehealth tool.
SpO2 is now integrated with Draganfly’s Vital Intelligence Assessment camera technology and is available on Draganfly’s Smart Vital Entrance Kiosks or for third party telehealth developers via an API.
“The blood oxygen gauge our team developed for the Vital Intelligence project shows the enormous potential of streaming video for remote detection of many health conditions,” said Dr. Javaan Chahl, Chief Scientist of Draganfly’s Vital Intelligence technology and Chair of Sensor Systems at the University of South Australia.
“The team at Draganfly has been working tirelessly on product advancements to help to ensure that our camera technology is effective in flattening the curve by screening key potential symptoms related to COVID-19 with the Vital Intelligence technology,” said Cameron Chell, Draganfly CEO. “This vital sign assessment of SpO2 along with heart rate, respiratory rate and other vital signs through video is a game changer in telehealth and overall health security in our society.”
Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspection, security, mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.
For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.
This news release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements include, but are not limited to, statements with respect the successful integration of SpO2 into the Company’s Vital Intelligence assessment technology. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.